Loading provider…
Loading provider…
Hematology & Oncology Physician in Miami, FL
NPI: 1427068154Primary Employer
UMiami Medicine - Medical Oncology
umiamihealth.org
HQ Phone
Get MD Raja's Phone Numberphone_androidMobile
Get MD Raja's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2006 - 2026
LA State Medical License
1995 - 2009

American Board of Internal Medicine
Medical Oncology
Duke University Hospital
Fellowship • Hematology and Medical Oncology
1992 - 1995
Residency • Internal Medicine
1989 - 1992
American University of Beirut Faculty of Medicine
Medical School
Until 1989
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 29 | 109 |
| 2 | 99212Established patient outpatient visit, total time 10-19 minutes | 16 | 38 |
Perspectives on the cancer death of a medical student.
Authors: Kahn, Marc J, Mudad, Raja, Glotzbach, Jason P, Owens, Donald P
Journal: Am J Hosp Palliat Care
Carcinoid syndrome with unknown primary: a case report.
Authors: Mahmood, T, Mudad, R
Journal: Am J Clin Oncol
Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines
Authors: Edgardo Santos, Luis Raez
Journal: Expert Rev Anticancer Ther
Lead Sponsor: GlaxoSmithKline
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: letetresgene autoleucel (GSK3377794)
Lead Sponsor: Adaptimmune
Intervention / Treatment: BIOLOGICAL: Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Clinical Observation, DRUG: Crizotinib